Issue Date: May 27, 2013
Elan Goes On A Spending Spree
Flush with money after having sold most of its assets, the Irish drug company Elan is remaking itself through acquisitions and investments. It’s a gutsy undertaking, and it could be thwarted by another company seeking to buy Elan for its cash and future royalties.
Under CEO G. Kelly Martin, Elan has been laying off staff, selling businesses, and paying down debt since 2009. Martin, a former Merrill Lynch executive who is known as . . .
You Do Not Have Access to C&EN Protected Content.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society